A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR101 in the Treatment of Subjects With Interstitial Lung Disease

NCT06825169 PHASE1, PHASE2 NOT_YET_RECRUITING

The target of this trial is to evaluate the safety, tolerability and preliminary efficacy of NCR101 in the treatment of subjects with interstitial lung disease. The trial contains Single ascending dose（SAD） and Multiple ascending dose（MAD）. Subjects will receive at least 1 dose of NCR101.

Details

Lead sponsor	Nuwacell Biotechnologies Co., Ltd.
Phase	PHASE1, PHASE2
Status	NOT_YET_RECRUITING
Enrolment	30
Start date	Sat Mar 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Sep 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Interstitial Lung Disease (ILD)

Interventions

• NCR101 injection